BC Innovations | Jul 31, 2017
Distillery Therapeutics

Neurology

INDICATION: Schizophrenia; depression Cell culture studies suggest inhibiting DISC1 - FBXW7 binding could help treat schizophrenia and major depressive disorder (MDD). In human neuroprogenitor cells (NPCs) differentiated from induced pluripotent stem (iPS) cells generated from skin...
BC Extra | Jul 20, 2017
Preclinical News

FBXW7-DISC1 complex linked to schizophrenia

In a paper, researchers showed that F-box and WD repeat domain containing 7 (FBXW7; FBW7) controls levels of a scaffold protein, disrupted in schizophrenia 1 (DISC1) , which is deficient in hereditary schizophrenia. The research suggests...
BC Innovations | Apr 21, 2017
Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
BC Innovations | Mar 17, 2011
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Myeloid leukemia cell differentiation protein (MCL1); f-box and WD repeat domain containing 7 (FBXW7; FBW7) In vitro and mouse studies...
BC Innovations | Mar 17, 2011
Targets & Mechanisms

MCL1's resistance story

Separate studies by Harvard Medical School and Roche 's Genentech Inc. unit have shown that increased levels of myeloid leukemia cell differentiation protein, an antiapoptotic protein in the B cell lymphoma 2 family, can enable...
BC Innovations | Jul 29, 2010
Targets & Mechanisms

Inhibiting E3 ligases

Separate groups of researchers have identified highly selective small molecule inhibitors of E3 ubiquitin ligase , 1,2 a large multi-subunit complex involved in protein degradation that has been considered difficult, if not impossible, to target. The...
BC Innovations | Jul 15, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer F-box and WD repeat domain containing 7 (FBXW7; FBW7) An allosteric inhibitor of FBXW7, a subunit of the E3 ubiquitin ligase SCFFBW7, could be...
BC Innovations | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Breast cancer F-box and WD repeat domain containing 7 (FBXW7); mammalian target of rapamycin (mTOR; FRAP; RAFT1) Studies in cell...
BC Innovations | Jul 31, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Target/marker /pathway Summary Licensing status Publication and contact information Cancer Nucleophosmin (nucleolar phosphoprotein B23, numatrin) (NPM1; NPM); F-box and WD-40 domain protein 7 (Fbxw7) In vivo studies suggest that targeting mutated...
Items per page:
1 - 9 of 9